Neurocrine Biosciences Total Current Liabilities

Neurocrine Biosciences (NBIX) currently reports a total current liabilities of $870M as of June 2026. That compares with $550M in the prior-year period — up 60.1% year over year. Use the charts on this page to explore Neurocrine Biosciences's total current liabilities history and peer comparisons.

Neurocrine Biosciences's total current liabilities increased from $550M to $870M — a 60.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Neurocrine Biosciences reported $870M in total current liabilities as of June 2026. That compares with $550M in the prior-year period — up 60.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $870M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Neurocrine Biosciences, and consider following NBIX for alerts when major investors trade the stock.

Neurocrine Biosciences is classified in the Healthcare sector. On total current liabilities, it currently shows $870M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBIX with unrelated industries.